Regeneron Pharmaceuticals Inc
LSE:0R2M
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Regeneron Pharmaceuticals Inc
LSE:0R2M
|
US |
|
Z
|
Zoom Video Communications Inc
F:5ZM
|
US |
|
Pagegroup PLC
OTC:MPGPY
|
UK |
|
Lu Hai Holding Corp
TWSE:2115
|
TW |
|
R
|
REA Group Ltd
SWB:R9C
|
AU |
|
Grand T G Gold Holdings Ltd
HKEX:8299
|
HK |
|
Danone SA
LSE:0KFX
|
FR |
|
China Mobile Ltd
SSE:600941
|
CN |
|
Deutsche Bank AG
NYSE:DB
|
DE |
|
P
|
Phillips 66
SWB:R66
|
US |
|
S
|
Sumitomo Electric Industries Ltd
SWB:SMO
|
JP |
|
A
|
Air China Ltd
LSE:AIRC
|
CN |
|
D
|
Deutsche Bank AG
XHAM:DBK
|
DE |
Wall St Price Targets
0R2M Price Targets Summary
Regeneron Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 0R2M is 885.06 USD with a low forecast of 666.68 USD and a high forecast of 1 109.98 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0R2M's stock price target?
Price Target
885.06
USD
According to Wall Street analysts, the average 1-year price target for 0R2M is 885.06 USD with a low forecast of 666.68 USD and a high forecast of 1 109.98 USD.
What is the Revenue forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Revenue has been 28%. The projected CAGR for the next 8 years is 5%.
What is the Operating Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
12%
The compound annual growth rate for Operating Income over the next 8 years is 12%.
What is the Net Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
8%
The compound annual growth rate for Net Income over the next 8 years is 8%.
